Tonix Pharmaceuticals (NASDAQ:TNXP) Trading 3.5% Higher – Here’s Why

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price traded up 3.5% on Friday . The company traded as high as $0.28 and last traded at $0.26. 29,962,066 shares were traded during mid-day trading, a decline of 57% from the average session volume of 68,989,281 shares. The stock had previously closed at $0.26.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a report on Thursday. They set a “hold” rating on the stock.

Tonix Pharmaceuticals Trading Up 2.7 %

The firm has a market capitalization of $49.13 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The firm’s 50 day moving average is $0.25 and its 200 day moving average is $0.33. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.

Tonix Pharmaceuticals (NASDAQ:TNXP) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. Equities analysts forecast that Tonix Pharmaceuticals Holding Corp. will post -17.63 earnings per share for the current year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.